Altimmune Beats Estimates, Yet Stock Slumps 15% YTD

On AUG 6 2026, ALT dropped by 1.04% within 24 hours to reach $0.00572, ALT dropped by 1.21% within 7 days, dropped by 2.23% within 1 month, and dropped by 50.26% within 1 year.

Strategic Pipeline Advancement and Clinical Milestones

Altimmune, Inc., a late clinical-stage biopharmaceutical company, continues to advance its lead program, pemvidutide, through critical phases of development for serious liver diseases. The company announced the initiation of the PERFORMA Phase 3 trial for pemvidutide in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH). This global registrational study is designed to evaluate the drug’s impact on fibrosis improvement, MASH resolution, and broader clinical outcomes, marking a significant escalation of the program into late-stage development.

Prior to this initiation, Altimmune reported positive topline results from the RECLAIM Phase 2 trial focusing on Alcohol Use Disorder. The data indicated that pemvidutide at a 2.4 mg dosage achieved a statistically significant and clinically meaningful reduction in heavy drinking days, meeting the trial’s primary endpoint. Additionally, important secondary endpoints were satisfied, reinforcing the drug’s potential utility across different metabolic and behavioral conditions.

Further supporting the pipeline’s momentum, new 48-week IMPACT Phase 2b data presented at the European Association for the Study of the Liver (EASL) 2026 conference highlighted significant metabolic improvements in MASH patients. The oral presentation, recognized as a "Best of EASL" feature, demonstrated meaningful reductions in triglycerides, cholesterol, and blood pressure. Concurrent improvements across multiple non-invasive markers and qFibrosis-measured fibrosis regression were observed, underscoring the convergence of pemvidutide’s effects on disease activity and fibrosis. AI-based digital pathology analyses further corroborated these findings.

Financial Outlook and Upcoming Catalysts

Investors are closely monitoring Altimmune’s financial health and upcoming reporting dates. The company is scheduled to report its Second Quarter 2026 financial results and provide a business update on August 12, 2026. This follows the release of First Quarter 2026 results, which disclosed $535 million in cash, cash equivalents, and short-term investments as of April 30, 2026. The strong balance sheet supports the ongoing clinical trials and operational expenditures.

Market analysts have adjusted their earnings expectations based on recent performance. Over the past 90 days, estimates for Altimmune’s loss per share have narrowed from $1.00 to $0.64 for both 2026 and 2027. Historically, the company has beaten earnings estimates in three of the trailing four quarters, with an average positive surprise of 15.81%. Despite this track record, Altimmune’s shares have declined 15% year to date.

The company’s stock currently carries a Zacks Rank #2 (Buy), distinguishing it from other biotech peers in the sector. While competitors like Spyre Therapeutics and Beam Therapeutics reported mixed or negative earnings surprises, Altimmune’s consistent beat rate and robust cash position provide a relative stability narrative. The initiation of the PERFORMA Phase 3 trial is expected to serve as a major catalyst, with the company maintaining its plan to advance pemvidutide through late-stage development stages.

Operational Context

Altimmune’s strategic focus remains on addressing unmet medical needs in liver diseases and alcohol use disorder. The transition of pemvidutide into a global Phase 3 registrational trial represents a pivotal moment for the company. By demonstrating efficacy in earlier phases across multiple indications, Altimmune aims to validate the drug’s broad therapeutic potential. The upcoming financial report on August 12 will likely provide further clarity on the company’s resource allocation and progress toward regulatory milestones.